NOX Shares Noxopharm Limited
ASX · ASXLast in our picks 2026-10-15 — not in the current list; analysis below is from that screen
Oncology pipeline offers asymmetric upside, though early-stage execution and financing risk remain material.
Future value: $0.09 (+80.00%) · 6-12 months
Signal breakdown
- ▸Pipeline optionality without confirmed near-term valuation target.
- ▾Below 50-day MA (-31.15%)
- ▸Volume 2.14× average — accumulation
- ▾Near 52-week low (0% of range)
- ▸~80% upside to price target
Is NOX a buy right now?
Trend: NOX is trading below the 50-day average (-30.00%), RSI 61 — neutral momentum, with a 3-month return of -40.24%.
Valuation & quality: fundamentals show net margin 0.0%.
Our screen: BUY (score 2) — Oncology pipeline offers asymmetric upside, though early-stage execution and financing risk remain material.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -14.30% | +16.70% | +28.60% | +0.00% | -11.10% | +12.50% | -33.30% | -16.70% |
Fundamentals
Technical signals
About Noxopharm Limited
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.